Combination advanced therapy use and infection risks in immune-mediated inflammatory diseases

Clicks: 3
ID: 338753
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #58 of 62 articles by views in international journal of rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: To evaluate real-world evidence on combination advanced therapy (CAT) exposures and safety in patients with immune-mediated inflammatory diseases (IMIDs). METHODS: We conducted a retrospective new-user cohort study of individuals initiating advanced therapies between 2016 to 2023 using MarketScan® databases. We assessed for overlapping (≥30 days) exposures to different targeted synthetic or biologic disease-modifying antirheumatic drug (ts/bDMARD) classes (CAT episodes). We described baseline characteristics and calculated multivariate hazard ratios (HRs) for first CAT episode persistence. We estimated HRs for first serious infection (i.e. requiring hospitalization or intravenous antibiotics) comparing combined versus single advanced therapy, stratified by CAT regimens and IMIDs. RESULTS: A total of 270,198 individuals initiated 693,375 advanced therapy episodes, including 38,456 (14.2%) who started 52,212 CAT episodes. The most common IMIDs among CAT users were psoriasis, inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis (AxSpA). Among CAT episodes, 51.2% involved TNFi exposure. Median duration of first CAT exposure was 42 days. CAT was associated with 5.2 serious infections per 100 person-years, yielding a HR of 1.61 (95% CI: 1.46-1.78) compared to monotherapy. Anti-adhesion agents combined with TNFi was associated with serious infection (HR 1.49, 95% CI 1.09-2.04) compared to other combinations. In IMID-stratified analysis, CAT (versus monotherapy) was associated with higher risk of serious infection across all diseases, except AxSpA. CONCLUSIONS: CAT was predominantly used within the spondyloarthritis umbrella of diseases. CAT exposure was associated with short duration and increased serious infection risk, although this risk varied by CAT regimen and underlying IMID.
Reference Key
openalex_W7225243493 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Timothy S.H. Kwok, Jessica Widdifield, Cristiano Soares de Moura, Sasha Bernatsky, Jeffrey R. Curtis, Vinod Chandran, Gilaad G. Kaplan, Proton Rahman, Denis Poddubnyy
Are you one of these authors? Claim your profile
Journal international journal of rheumatology
Year 2026
DOI
10.1093/rheumatology/keag623
URL
https://doi.org/10.1093/rheumatology/keag623
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.